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XBP-1, a transcription factor that drives the unfolded
protein response (UPR), is activated in B cells when they
differentiate to plasma cells. Here, we show that in the B
cells, whose capacity to secrete IgM has been eliminated,
XBP-1 is induced normally on induction of differentiation,
suggesting that activation of XBP-1 in B cells is a differ-
entiation-dependent event, but not the result of a UPR
caused by the abundant synthesis of secreted IgM.
Without XBP-1, B cells fail to signal effectively through
the B-cell receptor. The signalling defects lead to aberrant
expression of the plasma cell transcription factors IRF4
and Blimp-1, and altered levels of activation-induced cyti-
dine deaminase and sphingosine-1-phosphate receptor.
Using XBP-1-deﬁcient/Blimp-1-GFP transgenic mice, we
ﬁnd that XBP-1-deﬁcient B cells form antibody-secreting
plasmablasts in response to initial immunization; how-
ever, these plasmablasts respond ineffectively to CXCL12.
They fail to colonize the bone marrow and do not sustain
antibody production. These ﬁndings deﬁne the role of
XBP-1 in normal plasma cell development and have im-
plications for management of B-cell malignancies.
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Introduction
Plasma cell differentiation begins when a naive B cell recog-
nizes antigen through its B-cell receptor (BCR) in secondary
lymphoid organs. A functional BCR consists of a membrane-
bound IgM molecule and a disulﬁde-linked Iga/Igb hetero-
dimer. On antigen binding, the BCR is recruited into lipid rafts
and activated through phosphorylation of the immunorecep-
tor tyrosine-based activation motifs (ITAM) on Iga/Igb
(Pierce, 2002; Dykstra et al, 2003). Phosphorylated Iga/Igb
then recruits Syk kinase, which, after phosphorylation, trans-
duces signals eventually leading to regulation of transcription
factors. Plasma cell differentiation is achieved by downregu-
lation of the transcription factors BCL6 and Pax5, responsible
for maintaining the naive B-cell phenotypes, and by upregu-
lation of the canonical plasma cell transcription factors XBP-
1, Blimp-1 and IRF4 (Reimold et al, 2001; Shaffer et al, 2002;
Klein et al, 2006; Sciammas et al, 2006; Kallies et al,2 0 0 7 ;
Martins and Calame, 2008).
XBP-1 is one of the major transcription factors in plasma
cell differentiation, and its loss leads to an almost complete
absence of plasma cells and circulating immunoglobulins
(Reimold et al, 2001; Iwakoshi et al, 2003a,b). XBP-1 is a
basic-region leucine zipper type transcription factor that
belongs to the CREB/ATF family, and is one of the three
major arms of the unfolded protein response (UPR) in
mammals. When cells are treated with drugs such as tunica-
mycin and thapsigargin, or exposed to dithiothreitol, accu-
mulation of misfolded proteins is believed to occur, leading to
splicing of XBP-1 by transmembrane kinase and endoribonu-
clease inositol-requiring enzyme-1 (IRE-1) in an unconven-
tional cleavage and re-ligation reaction (Shen et al, 2001;
Yoshida et al, 2001; Calfon et al, 2002). On activation, spliced
XBP-1 (XBP-1s) regulates the synthesis of chaperones and
other proteins essential for restoration of proper secretory
function (Lee et al, 2003, 2005).
To form a fully functional plasma cell, a B cell needs to
expand its endoplasmic reticulum (ER) in preparation for
increased immunoglobulin secretion; activation of XBP-1 and
the UPR allows a B cell to rapidly increase the capacity of the
ER. The failure of XBP-1-deﬁcient B cells to generate plasma
cells is usually attributed to the accumulation of newly
synthesized immunoglobulin, not all of which may fold
correctly. The inability of XBP-1-deﬁcient B cells to activate
the normal UPR would then lead to ER obstruction caused by
an overload of misfolded immunoglobulin and, consequently,
cell death (Iwakoshi et al, 2003a,b; van Anken et al, 2003).
The current model of XBP-1 in plasma cell differentiation
assumes that immunoglobulin synthesis is initiated ﬁrst, and
that misfolded IgM triggers IRE-1-mediated splicing of XBP-1.
However, B-cell lines stimulated with lipopolysaccharide
(LPS) show XBP-1 activation before an increase in immuno-
globulin synthesis (Gass et al, 2002). XBP-1 is also activated
at the pro-B-cell stage in the bone marrow, despite the fact
that pro-B cells do not secrete large amounts of immunoglo-
bulin or any other known protein that could accumulate in
the ER and trigger XBP-1 activation (Brunsing et al, 2008).
How XBP-1 deﬁciency causes the failure of plasma cell
differentiation remains to be settled.
To investigate the role of XBP-1 in B-cell differentiation and
BCR signalling, we established a hen egg lysozyme (HEL)-
speciﬁc BCR transgenic (MD4) (Goodnow et al, 1988),
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1624conditional XBP-1 knockout mouse model, which allowed us
to examine the consequences of antigen-speciﬁc BCR activa-
tion in an XBP-1-deﬁcient background. Our data deﬁne XBP-1
activation as a differentiation-dependent event, rather than a
response to large quantities of secreted IgM in B cells. We
show that XBP-1 is required for proper signalling through the
BCR, whereas IL-4 and TLR signalling remains unchanged in
XBP-1-deﬁcient B cells. Lack of XBP-1 causes upregulation of
IRF-4 and Blimp-1, establishing an earlier unappreciated
feedback loop initiated by XBP-1. In addition, we track
plasma cells in vivo using immunized XBP-1
KO/MD4/Blimp-
1-GFP mice. We ﬁnd that XBP-1-deﬁcient mice have a robust
plasma cell population in the spleen and high titers of serum
antibodies after one immunization. This robust antibody
response is short lived due to a defect in the plasma cell
colonization of long-lived niches in the bone marrow.
Results
XBP-1
KO/MD4 B cells do not sustain antibody
secretion
To investigate the role of XBP-1 in B-cell responses to antigen,
we generated CD19-Cre XBP-1
ﬂox/ﬂox/MD4 transgenic
(XBP-1
KO/MD4) mice, in which 495% of B cells express a
BCR speciﬁc for the HEL. We examined the B-cell compart-
ment (bone marrow, peritoneal cavity and spleen) of XBP-
1
KO/MD4 mice and found normal numbers of B cells, includ-
ing pro-B, pre-B and immature B cells in bone marrow, as
well as normal B1 and B2 compartments in the peritoneal
cavity and spleen. Transitional B-cell populations, marginal
zone B cells and germinal centre B cells were also unaffected
by XBP-1 deﬁciency. The number of CD138
þ long-lived
plasma cells in the bone marrow and spleen was extremely
low in these mice, as they expressed the MD4 transgene and
had never been exposed to the relevant antigen, HEL (Figure
1A and B). We repeatedly immunized mice with HEL and
found that the anti-HEL IgM in the sera of XBP-1
KO mice was
signiﬁcantly lower than that of XBP-1
WT mice (Figure 1C; see
also Figure 7C), a phenotype consistent with the block in
plasma cell differentiation seen in XBP-1
 / /RAG2
 /  chi-
meric mice (Reimold et al, 2001). However, to our surprise,
unimmunized XBP-1
KO/MD4 mice had appreciable levels of
circulating antibody. These antibody levels were lower than
those seen in XBP-1
WT/MD4 mice. Although XBP-1 is
required for sustained antibody production, it can proceed
in the absence of XBP-1 (Figure 1C). Despite the link between
XBP-1 and the UPR, we conclude that at least some of the
serum antibodies in XBP-1
KO/MD4 mice are properly folded
as evidenced by their ability to bind antigen in an enzyme-
linked immunosorbent assay (ELISA) (Figure 1C).
Protein folding occurs normally in the absence of XBP-1,
and unfolded IgM is not required for XBP-1 activation
XBP-1 could operate in one of the two ways during plasma
cell differentiation. Either a ﬂood of newly synthesized IgM
into the ER activates XBP-1 to turn on the UPR, to handle this
increased secretory load, or XBP-1 is part of a network of
transcription factors that regulate plasma cell function inde-
pendent of secretory capacity. To test the ﬁrst hypothesis, we
looked for evidence of accumulation of unfolded proteins in
XBP-1-deﬁcient B cells. We stabilized potential protein
aggregates in lysates by cross-linking using bis[sulfosuccini-
midyl]suberate (BS
3) before analysis by SDS–PAGE. We did
not detect aggregated proteins in either XBP-1
WT/MD4 or
XBP-1
KO/MD4 B cells (Figure 2A). We induced aggregation of
ER-resident proteins by exposure of intact cells to thapsigar-
gin, a treatment expected to lead to collapse of calcium
gradients across the ER membrane, with a concomitant fail-
ure of calcium-dependent chaperones to assist in protein
folding. Thapsigargin treatment induced calreticulin-contain-
ing high molecular weight aggregates in both XBP-1
WT/MD4
and XBP-1
KO/MD4 cells to a similar degree. Thus, the pre-
sence of XBP-1 did not provide a protective effect against the
formation of these protein aggregates (Figure 2A).
To test the hypothesis that whether in normal B cells the
increase of secreted IgM is responsible for XBP-1 activation,
we stimulated naive B cells puriﬁed from the spleens of XBP-
1
WT/mS /  mice with LPS for 4 days. These B cells neither
produce secreted IgM on LPS stimulation (Boes et al, 1998)
(see below, Figure 3B), nor is there a massive increase in the
synthesis of membrane IgM. We observed XBP-1 activation in
both wild-type mS /  and MD4 B cells (Figure 2B;
Supplementary Figure S1), showing clearly that activation
of XBP-1 can occur in response to LPS-induced differentiation
in the absence of massively increased synthesis of secreted
IgM. The levels of XBP-1 decrease in mS /  B cells after 4
days in culture, whereas its levels in MD4 B cells keep
increasing (Figure 2B; Supplementary Figure S1), suggesting
that secreted IgM may play a role in sustaining high levels of
XBP-1 in the later stages of plasma cell differentiation.
We further examined whether the XBP-1-activating en-
zyme IRE-1 is expressed properly. We detected only small
amounts of IRE-1 protein in wild-type mS /  B cells even
after these cells were induced to differentiate in response to
LPS treatment for 4 days (Figure 2C). In XBP-1
KO/mS /  B
cells, we observed a massive increase of IRE-1 levels in a
differentiation-dependent manner, despite the fact that se-
creted IgM is absent in these B cells (Figure 2C). Similar
results were observed in XBP-1
KO and XBP-1
KO/MD4 B cells
(Supplementary Figure S1 and data not shown). The absence
of XBP-1 thus leads to increased synthesis of IRE-1 and shows
a negative feedback loop controlled by XBP-1.
XBP-1 deﬁciency affects synthesis but not surface
expression of membrane-bound IgM
To further investigate protein folding in XBP-1-deﬁcient B
cells, we focused primarily on proteins necessary for B-cell
function that were known to be produced in large quantities,
beginning with IgM. Pulse chase experiments were per-
formed in LPS-stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4
B cells, and membrane IgM was separated from secreted IgM
using Triton X-114 phase separation. XBP-1
KO/MD4 plasma-
blasts synthesized substantially less secreted IgM (Tirosh
et al, 2005) (Figure 3A) and released only small amounts of
IgM into the culture media (Figure 3A). XBP-1
KO/MD4 plas-
mablasts synthesized only slightly less membrane IgM than
XBP-1
WT/MD4 plasmablasts, but the trafﬁcking of membrane
IgM was normal, as assessed by acquisition of complex-type
N-linked glycans on membrane m chains (Figure 3A). The
mS /  system obviates the need for detergent-based IgM
separation, and rates of maturation of membrane IgM in XBP-
1
KO/mS /  plasmablasts were similar to that observed in
XBP-1
WT/mS /  plasmablasts (Figure 3B), conﬁrming
that intracellular transport of IgM is normal in the absence
XBP-1 regulates plasma cell development
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Figure 1 B cells from XBP-1
KO/MD4 mice fail to differentiate into plasma cells. (A, B) XBP-1 deﬁciency leads to reduced production of plasma
cells, whereas all other B-cell compartments of the XBP-1
KO mice appear normal. B cells were isolated from the bone marrow, peritoneal cavity
and spleen, and stained with indicated markers. Cells shown were gated on B220
þ or CD19
þ populations. The B-cell populations indicated in
each panel are as follows: (i) pro-B cells, (ii) pre-B cells, (iii) immature B cells, (iv) pro-B cells, (v) pre-B cells, (vi) immature B cells, (vii)
plasma cells, (viii) B-1 cells, (ix) transitional B cells, (x) follicular B cells, (xi) marginal zone B cells, (xii) T-1 transitional B cells, (xiii) T-2
transitional B cells, (xiv) germinal centre B cells and (xv) plasma cells. The numbers indicate the percentages of cells. (C) XBP-1
WT/MD4 and
XBP-1
KO/MD4 mice were not immunized. XBP-1
WTand XBP-1
KO mice were repeatedly immunized with HEL. The levels of anti-HEL IgM in the
sera were determined by ELISA.
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were observed when comparing naive or 1- to 3-day LPS-
stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4 B cells
(Figure 3C). Although surface expression of membrane IgM
after 4-day LPS stimulation was decreased by an average of
40% (as determined by mean ﬂuorescence intensity) on XBP-
1
KO/MD4 B cells, such differences were not seen when
comparing XBP-1
WT/mS /  and XBP-1
KO/mS /  B cells
(data not shown).
XBP-1 deﬁciency does not alter the synthesis
and assembly of Iga and Igb
As Iga and Igb are responsible for transduction of signals on
antigen binding to the BCR, we investigated whether there is a
defect in their synthesis, assembly and exit from the ER when
XBP-1 is absent. The synthesis of Iga and Igb was not affected
by the absence of XBP-1, as we detected similar amounts of Iga
and Igb in XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts
(Figure 3D). Iga and Igb contain two and three N-linked
glycosylation sites, respectively; only one glycosylation site
on Iga acquired endo-H-resistant complex glycans, whereas
all three sites of Igb acquired complex glycans (Figure 3D). As
Iga and Igb of XBP-1
KO/MD4 plasmablasts can acquire complex
glycans in the Golgi apparatus, their exit from the ER is normal
in the absence of XBP-1. To assess the association of Iga with
Igb, we cross-linked proteins in detergent lysates using BS
3 and
analysed the appearance of Iga/Igb heterodimers. We saw no
difference in Iga/Igb dimerization between XBP-1
WT/MD4 and
XBP-1
KO/MD4 plasmablasts (Figure 3E).
XBP-1-deﬁcient B cells show defective
phosphorylation of Iga,I g b and Syk on
antigen-speciﬁc activation of the BCR
B cells were harvested from the spleens of XBP-1
WT/MD4 and
XBP-1
KO/MD4 mice, cultured with LPS for 3 or 4 days and
activated with trimeric HEL as a physiological means of
engaging the BCR through its antigen-binding sites, rather
than by cross-linking through conserved portions of the BCR
(Kim et al, 2006). XBP-1-deﬁcient B cells showed an approxi-
mately six-fold reduction in phosphorylation of Iga and Igb
when compared with their wild-type counterparts
(Figure 4A), although total levels of Iga and Igb were
unaffected (Figure 3D and E). As phosphorylation of Syk
occurs immediately downstream of phosphorylation of Iga
and Igb, we examined kinetics of Syk phosphorylation in
response to trimeric HEL and observed that phosphorylation
of Syk is approximately four-fold stronger in XBP-1
WT/MD4
than in XBP-1
KO/MD4 B cells (Figure 4B).
Splenic B cells consist of B10% marginal zone and 90%
follicular B cells. We sorted marginal zone (CD23
medium,
CD1d
high) and follicular (CD23
high, CD1d
low) B cells and
found reduced Syk phosphorylation in both follicular and
marginal zone XBP-1-deﬁcient B cells (Supplementary Figure
S2), although the phosphorylation defect is more pronounced
in follicular B cells.
To determine when in the course of differentiation this
difference in response occurred, we compared total Syk levels
and HEL-induced Syk phosphorylation in B cells after expo-
sure with LPS over the course of 4 days (Figure 4C). Initially,
there was no difference in total or phosphorylated Syk levels
between naive XBP-1-proﬁcient and -deﬁcient B cells, when
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Figure 2 XBP-1 activation is a differentiation-dependent event in B
cells, and the lack of XBP-1 leads to IRE-1 upregulation. (A) XBP-1
deﬁciency does not lead to accumulation of misfolded proteins.
Four-day LPS-stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4 plasma-
blasts were treated with or without 30mM thapsigargin for 3h
before lysis. Lysates were treated with the indicated concentrations
of the cross-linker bis[sulfosuccinimidyl]suberate (BS
3) and immu-
noblotted for calreticulin. (B) B cells puriﬁed from spleens of either
XBP-1
WT/MD4 and XBP-1
KO/MD4 mice (upper three panels) or
XBP-1
WT/mS /  and XBP-1
KO/mS /  mice (lower three panels)
were cultured in LPS (20mg/ml) to induce differentiation. Cell
lysates were immunoblotted for XBP-1, p97 (AAA-ATPase) and
actin. (C) XBP-1
WT/mS /  and XBP-1
KO/mS /  B cells were
stimulated by LPS to induce differentiation. Lysates were immuno-
blotted for IRE-1, p97 and actin.
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LPS-induced differentiation, XBP-1
KO/MD4 B cells consis-
tently expressed higher levels of Syk than XBP-1
WT/MD4 B
cells (Figure 4D), but their ability to phosphorylate Syk in
response to HEL stimulation dropped signiﬁcantly after 3 and
4 days of LPS-induced differentiation (Figure 4E). Four-day
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Figure 3 Transport of membrane-bound IgM and the heterodimeric Iga/Igb to the cell surface appears to be normal in XBP-1-deﬁcient B cells.
(A) Four-day LPS-stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts were labelled by
35S-[methionine] and -[cysteine] for 10min and
chased for indicated time. Cells were lysed in Triton X-114 and lysates were subjected to phase separation. The intracellular membrane-bound
IgM was immunoprecipitated using the anti-m antibody from Triton X-114-associated protein fractions, whereas the intracellular secreted IgM
was immunoprecipitated from Triton X-114 supernatant fractions. The extracellular secreted IgM was immunoprecipitated from the culture
media. The asterisk denotes endo-H-resistant complex glycans. (B) Four-day LPS-stimulated XBP-1
WT/mS /  and XBP-1
KO/mS /  plasma-
blasts were radiolabelled for 10min and chased for indicated time. Lysates were immunoprecipitated using the anti-m antibody. (C) Naive
XBP-1
WT/MD4 and XBP-1
KO/MD4 B cells were stimulated by LPS for 4 days to allow differentiation. Each day cells were surface-stained by
an FITC-conjugated anti-m antibody and analysed by ﬂow cytoﬂuorimetry. (D) Three-day LPS-stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4
plasmablasts were lysed. Lysates were treated with either endo-H or PNGase F before immunoblotting for Iga or Igb. CHO, CHO* and
NAG represent high mannose-type glycans, complex-type glycans and N-acetylglucosamines, respectively. (E) Four-day LPS-stimulated
XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts were lysed. Lysates were cross-linked with BS
3 of indicated concentrations and analysed by
immunoblot for Iga or Igb.
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relative amounts of Syk versus phospho-Syk in XBP-1
KO/MD4
versus XBP-1
WT/MD4 B cells. In the same experiment, we
observed that the expression of calnexin was more differen-
tiation dependent than that of calreticulin and the AAA
ATPase (p97). The expression level of protein disulﬁde iso-
merase (PDI) was not only differentiation dependent, but also
XBP-1 dependent (Figure 4C).
Defective BCR signalling in XBP-1-deﬁcient B cells leads
to reduced production of IL-6
We treated naive and 3-day LPS-induced B cells with IL-4 for
4 and 24h, respectively, and examined the phosphorylation
status of Stat6 (signal transducers and activators of transcrip-
tion-6). We detected no difference in Stat6 phosphorylation
between XBP-1-proﬁcient and -deﬁcient cells in response to
IL-4 stimulation, showing that—unlike signalling through the
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Figure 4 XBP-1 deﬁciency causes defective phosphorylation of Iga,I g b and Syk in LPS-induced plasmablasts on antigen engagement. (A) LPS-
stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts were activated by trimeric HEL for 2min and lysed immediately. Lysates were
immunoprecipitated using anti-Iga and anti-Igb antibodies. The immunoprecipitates were analysed by SDS–PAGE and immunoblotted using an
anti-phospho-Iga antibody or an anti-phosphotyrosine antibody. Total lysates were immunoblotted using an anti–actin antibody as a loading
control. (B) XBP-1 plays a role in the maintenance of persistent Syk phosphorylation on BCR activation. Day 4 LPS-stimulated XBP-1
WT/MD4
and XBP-1
KO/MD4 plasmablasts were stimulated with trimeric HEL for indicated time and lysed immediately. Lysates were immunoblotted for
phospho-Syk, Syk, actin, p97 and calreticulin. Quantitation of protein bands was performed, and the numbers represent relative band intensity
within each gel. (C) Naive XBP-1
WT/MD4 and XBP-1
KO/MD4 B cells were induced to differentiate into plasmablasts by LPS. At the end of each
indicated LPS stimulation time, cells were exposed to trimeric HEL for 2min and lysed immediately. Day 0 cells were not exposed to LPS.
Lysates were immunoblotted for phospho-Syk, Syk, protein disulﬁde isomerase (PDI), calnexin, calreticulin, p97 and actin. Note the
imbalanced Syk phosphorylation between XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts from day 1 to day 4. (D) Protein bands in the
Syk immunoblot in (C) were quantiﬁed and data were plotted as fold changes. (E) Protein bands in the phospho-Syk immunoblot in (C) were
quantiﬁed.
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cells (Figure 5A).
Although secreted IgM is the most commonly used readout
for B-cell activation, XBP-1-deﬁcient B cells have a known
defect in the synthesis of secreted IgM, and thus we measured
B-cell activation in response to various stimuli by IL-6
production instead. Naive, 2- and 4-day LPS-induced XBP-1-
deﬁcient B cells secreted signiﬁcantly less IL-6 than their
wild-type counterparts when stimulated with antibodies
against IgM or with trimeric HEL, but not with LPS or CpG
(Figure 5B–D). Sorted XBP-1-deﬁcient follicular B cells also
secreted less IL-6 when stimulated with trimeric HEL
(Figure 5E). We conclude that signalling through Toll-like
receptor (TLR)-4 and TLR-9 is normal. Treatment of XBP-1-
deﬁcient B cells with exogenous IL-4 or IL-6 did not restore
the production of secreted IgM (Supplementary Figure S3).
XBP-1 deﬁciency leads to upregulation of IRF-4
and Blimp-1, and altered levels of activation-induced
cytidine deaminase
As signalling through the BCR is compromised by XBP-1
deﬁciency (Figure 4; Supplementary Figure S2), we investi-
gated the effect of XBP-1 deﬁciency on transcription factors
downstream of BCR activation. Surprisingly, in XBP-1-deﬁ-
cient B cells, IRF4 and Blimp-1, both of which control plasma
cell differentiation, were present at elevated levels
(Figure 6A). A relative increase in Blimp-1 likewise occurred
in XBP-1-deﬁcient B cells in response to engagement of
diverse TLR agonists (Supplementary Figure S4). Pax5 and
BCL6, transcription factors associated with the naive B-cell
state, were unaffected by the lack of XBP-1, and on B-cell
differentiation their levels declined as expected, indepen-
dently of XBP-1 status (Figure 6A). Similar upregulation of
IRF4 and Blimp-1 was observed in XBP-1
KO/MD4 B cells
(Supplementary Figure S5).
IRF4 regulates activation-induced cytidine deaminase
(AID) expression, class switching and plasma cell differentia-
tion (Klein et al, 2006; Sciammas et al, 2006). Expression of
AID depends on LPS-induced differentiation and declines in
XBP-1-deﬁcient B cells (Figure 6B), although IRF4 levels are
elevated in these cells (Figure 6A; Supplementary Figure S5).
Blimp-1-GFP-positive plasma cells of HEL-immunized
XBP-1
KO/MD4/Blimp-1-GFP mice do not colonize the
bone marrow
Sphingosine-1-phosphate receptor (S1P1) controls the migra-
tion of lymphocytes from secondary lymphoid organs into the
circulation, followed by their homing to the respective target
sites (Rosen and Goetzl, 2005; Schwab and Cyster, 2007).
S1P1 levels drop in 2-day LPS-stimulated B cells and rise
again in 4-day LPS-stimulated B cells (Figure 6B), a pattern
similar to that reported for activated Tcells (Matloubian et al,
2004). XBP-1 deﬁciency leads to upregulation of the S1P1 in
naive and 4-day LPS-stimulated B cells (Figure 6B). To
examine plasma cell homing in vivo, we immunized XBP-
1
KO/MD4/Blimp-1-GFP mice with HEL and analysed the
formation of Blimp-1-GFP-positive plasma cells. Blimp-1-
GFP-positive plasmablasts arose in the spleens of HEL-im-
munized XBP-1
KO/MD4/Blimp-1-GFP mice, and their number
decreased in mice immunized twice or three times (Figure 7A
and B). As plasmablasts usually migrate to long-lived niches
in the bone marrow for sustained antibody production, we
looked for the arrival of such cells in the bone marrow.
However, signiﬁcantly fewer XBP-1-deﬁcient Blimp-1-GFP-
positive plasma cells migrated to and colonized the
bone marrow when compared with XBP-1-proﬁcient mice
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Figure 5 IgM- or HEL-stimulated XBP-1-deﬁcient B cells produce less IL-6. (A) Naive B cells were cultured in the media with or without IL-4
for 4h, and some cells were subsequently stimulated by trimeric HEL for 2min. Besides, naive B cells were cultured in LPS for 3 days and
subsequently treated with IL-4 for another 24h. Lysates were immunoblotted for phospho-Stat6 (upper panels) and actin (lower panels). Naive
(B), 2-day LPS stimulated (C) and 4-day LPS stimulated (D) XBP-1
WT/MD4 and XBP-1
KO/MD4 B cells were cultured with plate-bound LPS,
CpG, anti-IgM or HEL. (E) Sorted XBP-1
WT/MD4 and XBP-1
KO/MD4 follicular B cells (using CD1d and CD23 markers) were stimulated with LPS
for 4 days and then cultured with plate-bound HEL. The level of secreted IL-6 in the culture supernatants was measured after 24h by ELISA.
*Po0.005.
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KO/MD4/Blimp-1-GFP
mice initially responded to immunization by producing
anti-HEL antibodies, the HEL-speciﬁc antibody titers rapidly
decreased in XBP-1
KO/MD4/Blimp-1-GFP mice immunized
more than once (Figure 7C). Decreased bone marrow coloni-
zation could be due to impaired CXCR4 signalling through
interaction with CXCL12, a chemokine secreted by bone
marrow stromal cells. Indeed, XBP-1-deﬁcient plasmablasts
phosphorylate ERK1/2 less efﬁciently than their wild-type
counterparts in response to stimulation with CXCL12
(Figure 7D).
Discussion
XBP-1 is required for the formation of plasma cells as well as
several other secretory cell types, including exocrine gland
acinar cells and Paneth cells (Lee et al, 2005; Kaser et al,
2008). Usually triggered by ER stress-induced IRE-1 activa-
tion, XBP-1 drives the expression of numerous genes in-
volved in glycoprotein folding and ER homeostasis, with
the overall effect of increasing secretory capacity. Thus, the
favoured hypothesis for XBP-1 function in plasma cell devel-
opment is as follows. Activated B cells rapidly increase
production of secreted IgM, some fraction of which is mis-
folded and accumulates in the ER. Misfolded IgM binds to the
chaperone BiP, titrating BiP away from IRE-1. IRE-1 di-
merizes, self-activates and initiates the splicing of xbp-1
transcripts. The translation product, XBP-1s, then upregulates
transcription of ER chaperones, relieving ER stress and
allowing the nascent plasma cell to continue producing
IgM. In the absence of XBP-1, misfolded IgM presumably
accumulates in the ER and leads to apoptosis, thus explaining
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Figure 6 XBP-1 deﬁciency leads to altered expression of IRF4, Blimp-1, activation-induced cytidine deaminase (AID) and sphingosine-1-
phosphate receptor (S1P1). (A) XBP-1
WT/mS /  and XBP-1
KO/mS /  B cells were cultured in LPS to induce differentiation for indicated time.
Lysates were immunoblotted for IRF4, Blimp-1, Pax5, BCL6, p97 and actin. (B) XBP-1
WTand XBP-1
KO B cells were stimulated by LPS to induce
differentiation. Lysates were immunoblotted for AID, S1P1 and p97. (C) A model that illustrates the inhibitory effect of XBP-1 on IRF4, Blimp-1
and its activating enzyme IRE-1. The red arrows indicate that the function of IRF4 and Blimp-1 to regulate plasma cell differentiation requires
XBP-1.
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Figure 7 XBP-1-deﬁcient plasma cells mount only a short lived but robust antibody response due to their failure to colonize into the bone
marrow. (A) XBP-1
WT/MD4/Blimp-1-GFP and XBP-1
KO/MD4/Blimp-1-GFP mice were immunized with HEL at the following time points: days
 34,  20 and  7( 3   immunized); days  20 and  7( 2   immunized); day  7( 1   immunized); or unimmunized (0  immunized).
Splenocytes and bone marrow cells from all these mice were isolated on the same day (day 0), stained for CD138 and analysed by ﬂow
cytometry. The percentage of Blimp-1-GFP-positive/CD138-positive cells is indicated in the upper right quadrants. The results are
representative of two independent experiments. Note that very few cells (0.05 and 0.09%) in the bone marrow of XBP-1
KO/MD4/Blimp-1-
GFP mice are Blimp-1-GFP-positve and CD138-positive after reimmunization. (B) The percentages of CD138þ/Blimp-1-GFPþ B cells from the
spleens and bone marrow of immunized mice (shown in A) were plotted. (C) HEL-speciﬁc antibody titers in the sera from mice described in (A)
were measured by ELISA. (D) Day 4 LPS-stimulated XBP-1
WT/MD4 and XBP-1
KO/MD4 plasmablasts were stimulated with CXCL12 for indicated
time and lysed immediately. Lysates were immunoblotted for phospho-ERK1/2, ERK1/2 and actin.
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et al, 2003a,b).
The current model of XBP-1 in plasma cells leads to two
testable hypotheses. First, it is misfolded IgM that triggers
XBP-1 activation, and second, XBP-1-deﬁcient B cells would
be expected to have an increase in misfolded proteins.
Neither of these hypotheses is supported by the data shown
here. B cells from XBP-1
WT/mS /  mice can neither produce
secreted IgM, nor do they show an increase in membrane-
bound IgM during LPS-induced differentiation. Although
class-switching rescues serum immunoglobulin levels in
vivo, LPS-stimulated XBP-1
WT/mS /  LPS plasmablasts
show virtually no evidence of switching to other isotypes,
as showed by the complete lack of any immunoglobulin
heavy chains recovered by immunoprecipitation of kappa
chains from culture supernatants (McGehee et al, manuscript
in preparation). Nonetheless, XBP-1
WT/mS /  plasmablasts
activate XBP-1 with similar kinetics as do XBP-1
WT/MD4
plasmablasts (Figure 2B; Supplementary Figure S1), demon-
strating conclusively that XBP-1 activation is a differentia-
tion-dependent event unlinked to accumulation of misfolded
IgM. Formally, we cannot exclude the possibility that proteins
other than IgM fail to fold properly when B cells initiate their
terminal differentiation programme, and so trigger the UPR.
However, for the glycoproteins examined, we observed no
obvious folding or trafﬁcking defects.
To directly assess the degree of misfolded proteins in XBP-
1-deﬁcient B cells, we cross-linked plasmablast lysates and
identiﬁed misfolded glycoproteins by their aggregation and
association with calreticulin and calnexin (Figure 2A and
data not shown). We found no evidence for a global increase
in misfolded proteins in XBP-1-deﬁcient plasmablasts.
Furthermore, close examination of individual proteins rele-
vant to B-cell function showed no defects in their folding.
IgM, both membrane-bound and secreted forms, trafﬁcked
through the ER at similar rates (Figure 3A and B) independent
of XBP-1 status. The resulting secreted IgM from wild-type
and XBP-1-deﬁcient plasmablasts was properly folded, as
assessed by its ability to bind antigen, both in an ELISA
and by binding to antigen-coated beads (Figure 1C; McGehee
et al, manuscript in preparation). Iga and Igb folding was also
normal in the absence of XBP-1 as assessed by rate of
synthesis, acquisition of complex glycans, disulﬁde bond
formation and heterodimer stability (Figure 3D and E;
McGehee et al, manuscript in preparation). A variety of
B-cell glycoproteins, such as MHC I, MHC II, CD1d, CD40,
CD80 and CD86, are expressed normally on the surface of
XBP-1-deﬁcient plasmablasts (McGehee et al and data not
shown). IL-6, itself a glycoprotein, is secreted normally from
XBP-1-deﬁcient plasmablasts on ligation of TLRs (Figure 5B
and C). Signalling through the IL-4 receptor and through
TLRs 4 and 9 is uncompromised in XBP-1-deﬁcient B cells,
providing further evidence that these receptors are functional
and properly folded (Figure 5A–C).
To better understand the role of XBP-1 in plasma cell
differentiation and the defects in XBP-1-deﬁcient cells, we
analysed the B cell-speciﬁc XBP-1 knockout/MD4 transgenic
(XBP-1
KO/MD4) mouse, in which B cells express an HEL-
speciﬁc BCR encoded by a transgene (Goodnow et al, 1988).
As anti-IgM reagents do not interact directly with the antigen-
binding site, activation of MD4 B cells by trimeric HEL serves
as physiological means to cross-link the BCR and explore
signalling alterations in the absence of XBP-1 (Kim et al,
2006).
XBP-1-deﬁcient MD4 plasmablasts showed a greatly di-
minished response to antigen stimulation, producing far less
IL-6 than their wild-type counterparts (Figure 5). Closer
examination of proximal signalling in XBP-1-deﬁcient plas-
mablasts showed impaired phosphorylation of Iga,I g b and
Syk on BCRengagement (Figure 4; Supplementary Figure S2).
XBP-1-deﬁcient plasmablasts showed a slight increase in Syk
phosphorylation when tested after 2 days of LPS culture
(Figure 4C and E), but this apparent increase in proximal
signalling did not rescue the diminished IL-6 production on
BCR engagement (Figure 5C). Both follicular and marginal
zone LPS-stimulated B cells showed impaired signalling
(Figure 5E; Supplementary Figure S2). Heterogeneity of the
total LPS-induced plasmablast populations, therefore, cannot
explain the differences observed in BCR signalling between
wild-type and XBP-1-deﬁcient plasmablasts. Furthermore,
XBP-1-deﬁcient plasmablasts responded normally to IL-4,
CpG and LPS stimulation (Figure 5), indicating that signalling
downstream of the IL-4 receptor and TLRs 4 and 9 is
unaffected by the absence of XBP-1.
How the transcription factor XBP-1 could affect BCR
signalling is not immediately obvious. Surface expression of
IgM is modestly diminished in XBP-1-deﬁcient plasmablasts,
but only after 4 days of culture (Figure 3C), whereas signal-
ling defects are observed earlier (Figure 4C–E). IgM produced
by XBP-1-deﬁcient MD4 B cells is fully capable of antigen
binding, and IL-6 production by XBP-1-deﬁcient MD4 plas-
mablasts cannot be rescued by increasing the concentration
of trimeric HEL used for stimulation (Figure 1C and data not
shown). Several mechanisms could contribute to the BCR-
speciﬁc signalling defect in XBP-1-deﬁcient cells. First,
although we found no evidence for protein misfolding in
the absence of XBP-1, we cannot exclude the possibility that
some proteins necessary for B-cell function are misfolded or
abnormally glycosylated. Full engagement of the BCR re-
quires not only the antigen-binding membrane IgM and its
signalling accessories, Iga/Igb, but also co-receptor proteins,
such as CD21 and CD81. Any defect in assembly or modiﬁca-
tion of these proteins as a result of downregulated PDI
(Figure 4C) altered terminal glycosylation or other as yet
unidentiﬁed alterations could compromise activation of the
BCR. Some differences in glycosylation were observed in
XBP-1-deﬁcient cells (McGehee et al, manuscript in prepara-
tion), but the functional importance of these altered terminal
glycans in BCR signalling has yet to be explored.
Furthermore, the expression of XBP-1 massively induces
phosphatidylcholine synthesis and increases transcription of
several other genes involved in lipid synthesis and metabo-
lism (Sriburi et al, 2004, 2007). Changes in lipid composition
caused by the lack of XBP-1 may lead to failure of assembling
functional lipid raft domains, which are critical for BCR
clustering on engagement of antigen. Indeed, we have ob-
served a decrease in sphingomyelin and phosphatidylinositol
content in membranes of XBP-1-deﬁcient B cells (McGehee
et al, manuscript in preparation). Sphingomyelin is an im-
portant component of lipid rafts, and phosphatidylinositol is
an essential intermediate in signalling pathways involving
phosphatidylinositol-3-phosphate.
Despite the defects in BCR signalling, XBP-1
KO/MD4 mice
have normal numbers of B cells and B-cell subsets (Figure 1A
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signiﬁcant alterations in signalling still produce B cells, albeit
with slight shifts in the ratios of marginal zone, follicular and
B-1 B cells (Pillai et al, 2004). However, BCR signal strength
determines B-cell subset fate in the bone marrow during the
immature stage of B-cell development. The large differences
in BCR signalling reported here were observed predominately
after LPS stimulation (Figure 4) at a time when XBP-1 spliced
protein is also present (Figure 2B; Supplementary Figure S1).
Thus, B cells in XBP-1 knockout mice are predicted to be
similar to the point when they ﬁrst contact the antigen. We do
observe some baseline differences in S1P1 expression by
naive XBP-1-deﬁcient splenic B cells (Figure 6B). Although
naive B cells do not express XBP-1, expression of XBP-1 in
pro-B cells could affect B-cell development (Brunsing et al,
2008).
Blimp-1 is a transcriptional repressor essential for plasma
cell development. IRF4 controls transcription of the Blimp-1
gene prdm1 by direct binding to a conserved noncoding
sequence between exons 5 and 6 (Sciammas et al, 2006).
Although earlier studies have shown that irf4 and prdm1 are
neither direct nor indirect targets of XBP-1 (Acosta-Alvear
et al, 2007), we observed that both IRF4 and Blimp-1 protein
levels are upregulated in XBP-1-deﬁcient plasmablasts
(Figure 6A; Supplementary Figure S5). We, therefore, propose
that XBP-1 inhibits the expression of IRF4, and consequently
Blimp-1, in plasma cells (Figure 6C). Given that IRF4 and
Blimp-1 can be expressed in the absence of XBP-1, XBP-1
must be placed downstream of both of these factors, an
observation consistent with earlier data showing that IRF4
and Blimp-1 increase xbp-1 transcription (Shaffer et al, 2002;
Klein et al, 2006). XBP-1 activation is also regulated post-
transcriptionally by IRE-1-mediated splicing to remove 26
nucleotides from xbp-1 mRNA. Of note, XBP-1 deﬁciency
greatly enhances IRE-1 protein levels (Figure 2C;
Supplementary Figure S1), demonstrating feedback inhibi-
tion of XBP-1 expression on IRE-1, similar to what is seen in
hepatocytes (Lee et al, 2008).
We propose that XBP-1 activation in B cells is a differentia-
tion-dependent event, and that the failure of XBP-1-deﬁcient
B cells to become plasma cells involves misregulation of key
transcription factors, possibly due to altered BCR signalling.
Paradoxically, loss of XBP-1 leads to increased IRF4 levels,
which cause an increase in Blimp-1, both key transcription
factors in plasma cell differentiation. However, despite higher
levels of these canonical plasma cell proteins, XBP-1-deﬁcient
B cells still do not become plasma cells. This block is
apparent not only by the lack of antibody secretion, but
also by decreased expression of AID (Figure 6B), a key
enzyme in class switch recombination and somatic hypermu-
tation. Thus, at least in tissue culture, XBP-1-deﬁcient B cells
appear poised to become plasma cells, yet fail to do so.
To analyse plasma cell formation in vivo, we immunized
XBP-1
KO/MD4/Blimp-1-GFP mice, which express GFP under
control of the Blimp-1 promoter to allow the unambiguous
quantitation of plasma cells by ﬂow cytometry. To our
surprise, XBP-1-deﬁcient mice developed a robust plasma-
blast population in the spleen after a single immunization,
which correlated with transiently elevated serum levels of
anti-HEL antibodies. On successive immunizations, however,
the spleen plasmablast population decreased and no plasma
cell population could be found accumulating in the bone
marrow (Figure 7A and B). Speciﬁc antibody titers also
declined in the XBP-1-deﬁcient animals with each subsequent
immunization (Figure 7C). The half-life of serum IgM in the
mouse is 2 days (Vieira and Rajewsky, 1988). Consequently,
although XBP-deﬁcient mice can mount a primary antibody
response, they do not sustain production of serum antibodies
even after reimmunization.
Annexin V staining of spleen plasma cells at each time
point showed no differences in apoptosis between wild-type
and XBP-1-deﬁcient cells (data not shown). CXCL12,
produced by stromal cells, and its receptor CXCR4 are
primarily responsible for homing of plasma cell precursors
to the bone marrow niches (Muehlinghaus et al, 2005).
CXCR4 is expressed normally on the surface of XBP-1-deﬁ-
cient plasma cells, but signalling through CXCR4 is impaired,
as shown by decreased ERK1/2 phosphorylation in
XBP-1-deﬁcient plasmablasts exposed to CXCL12
(Figure 7D). The blunted response to CXCL12 could in part
account for the failure of XBP-1-deﬁcient plasma cells to
colonize the bone marrow. In addition, IL-6 contributes to
plasma cell maintenance, and immunoglobulin itself has
been proposed to sustain long-lived plasma cells, although
the mechanism responsible is not clear (Iwakoshi et al,
2003a; Kumazaki et al, 2007). Decreased serum antibody
titers and decreased IL-6 produced by B cells could contribute
to the lack of long-lived plasma cells in the bone marrow of
XBP-1-deﬁcient mice. However, given that XBP-1-deﬁcient
MD4 mice in this study have measurable baseline serum
antibodies in the same order of magnitude as wild-type
MD4 mice (Figures 1C and 7C), and given that IL-6 is
produced by many cell types other than B cells, we propose
that failure of plasma cells to trafﬁck to the bone marrow is
the major cause of lack of sustained antibody production in
XBP-1-deﬁcient mice.
The short burst of antibody production observed in im-
munized XBP-1
KO/MD4/Blimp-1-GFP mice is at odds with
earlier reports showing that immunized XBP-1-deﬁcient mice
have lower serum levels of speciﬁc antibodies (Reimold et al,
2001). This discrepancy could be due to the different time
points at which the immunized mice were analysed, given
that the antibody production we observed occurred only
brieﬂy, and only after a single immunization. Alternatively,
the MD4 BCR is expressed from a transgene on 495% of B
cells, including B-1 cells in the peritoneal cavity and extra-
follicular B cells. Thus, immunization in MD4 mice could
induce antibody production primarily from these sources,
which would not be a major contributing factor in mice with
a polyclonal repertoire.
XBP-1 is upregulated in many human malignancies,
particularly multiple myeloma, a cancer for which few treat-
ment options are available. Overexpression of XBP-1 in B
cells is sufﬁcient to cause a monoclonal gammopathy
of undetermined signiﬁcance in mice, suggesting that
abnormal expression of XBP-1 could be a predisposing
factor for the development of myeloma (Carrasco et al,
2007). Our ﬁnding that XBP-1 activation precedes the
UPR in normal plasma cell development offers an
attractive possibility. If IRE-1-mediated splicing of XBP-1 is
triggered by a speciﬁc differentiation-dependent event rather
than by the accumulation of misfolded aggregates, then
XBP-1 activation itself may be an attractive target for drug
therapy.
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Mice
We generated CD19-Cre XBP-1
f/f/MD4 (XBP-1
KO/MD4) (Good-
now et al, 1988; Hetz et al, 2008), XBP-1
KO/MD4/Blimp-1-GFP
(Kallies et al, 2004) and XBP-1
KO/mS /  mice (Boes et al, 1998) by
crossing relevant strains. All animals were maintained according to
the MIT Committee on Animal Care.
Antibodies and reagents
Antibodies were raised against Iga,I g b (rabbit polyclonal) and
phospho-ITAMs of Iga and Igb (mouse monoclonal). Antibodies to
XBP-1 (Santa Cruz), Blimp-1 (Santa Cruz), IRF4 (Cell Signaling),
Pax5 (Santa Cruz), BCL6 (Cell Signaling), Syk (Cell Signaling),
phopho-Syk (Cell Signaling), lyn (Cell Signaling), phospho-Stat6
(Cell Signaling), IRE-1a (Cell Signaling), eIF2a (Cell Signaling), AID
(Cell Signaling), p44/42 MAPK (Cell Signaling), phospho-p44/42
MAPK (Cell Signaling), CD19 (Santa Cruz), S1P1 (Santa Cruz), actin
(Sigma), calreticulin (Stressgen), p97 (Fitzgerald), phosphotyrosine
(Upstate) and m (SouthernBiotech) were obtained commercially.
Antibodies for ﬂow cytometry were from BD Pharmingen: IgM (11/
41 or R6-60.2), IgD (11-26c.2a), CD1d (1B1), CD19 (MB19-1), CD23
(B3B4), CD43 (1B11), CD138 (281-2), B220 (RA3-6B2), AA4.1 and
GL7. Trimeric HEL and anti-PDI were produced in our laboratory.
Anti-calnexin was kindly provided by Dr David B Williams
(University of Toronto, Canada). LPS and CpG DNA were from
Sigma and TIB-MOLBIOL, respectively.
Cell culture
Naive B lymphocytes were puriﬁed from mouse spleen by magnetic
depletion of CD43-positive cells (Miltenyi Biotech). Naive B cells
were cultured in RPMI 1640 media containing 10% FBS with or
without LPS (20mg/ml). Marginal zone and follicular B cells were
stained with anti-CD1d and anti-CD23 antibodies and sorted using
an FACS Aria (BD Biosciences).
Immunization
Mice were immunized, intraperitoneally, with HEL (50mg) mixed in
complete or incomplete Freund’s adjuvant (Sigma).
BCR activation, SDS–PAGE and immunoblot
B cells were activated by trimeric HEL (5mg/ml) for 2min unless
indicated and lysed as described (Kim et al, 2006). Proteins were
resolved by SDS–PAGE, transferred to nitrocellulose and immuno-
blotted by conventional methods. In some cases, proteins were
treated with endoglycosidase H or PNGase F (New England
Biolabs). For cross-linking, proteins were treated with BS
3 (Pierce).
Quantitation of protein bands was performed using the Image
Gauge Version 3.0. (Fujiﬁlm).
Pulse chase labelling and immunoprecipitation
Plasmablasts were starved in methionine- and cysteine-free media
containing dialysed serum for 1h, and then pulse labelled for
10min with 250mCi/ml of [
35S]-methionine and [
35S]-cysteine. At
the end of each chase point, cells were rinsed twice with PBS and
lysed in conventional RIPA buffer containing protease inhibitors.
Pre-cleared lysates were incubated with a primary antibody and
Protein G-agarose beads, washed, eluted from the beads using
reducing Laemmli SDS–PAGE sample buffer and analysed by
SDS–PAGE.
Enzyme-linked immunosorbent assay
ELISA analyses of IL-6 production were performed according to the
manufacturer’s instruction (BD Biosciences). ELISA plates were
read using SpectraMax M2 microplate reader (Molecular Devices).
FACS analysis
Live B cells were stained with indicated antibodies and analysed by
an FACSCalibur ﬂow cytometer (BD Biosciences).
Triton X-114 phase separation
B cells were lysed in Triton X-114 lysis buffer (10mM Tris–HCl, pH
7.4; 150mM NaCl; 1% Triton X-114) containing protease inhibitors.
Phase separation was performed as described by Bordier, 1981.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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